November 04, 2025

Get In Touch

Sickle Cell Disease Tied To Significantly Elevated Risk Of Retinal Vascular Occlusion: Study

A study by Kaufmann and team examined the risk of big artery retinal vascular occlusion (RVO) in a large national US database and found that individuals with sickle cell disease (SCD) who had hemoglobin SS (HbSS) posed a much greater risk. The key findings of this study were published in the Ophthalmology Retina journal.
SCD affects about 100,000 individuals in the US, and it costs the healthcare system over $3 billion a year. Despite RVO has been documented in published research to occur in SCD patients, including bilateral occlusions, the actual risk of RVO is still unclear. Also, no research has assessed the risk of RVO in the US population as a whole or in strata based on hemoglobin mutation previously. This study assessed the risk of venous and arterial RVO in individuals with different β-globin mutations by this study.
94 million patients were included in the cross-sectional and retrospective cohort research from 2006 to 2024 using the national database of the TriNetX US Collaborative Network. The patients with sickle cell were included using the ICD-10 codes, such as sickle cell trait, hemoglobin SCD (HbSC), or sickle cell disease (SCD) (HbSS). Propensity score matching was used to create matched control cohorts based on factors such as age, race, sex, ethnicity, diabetes, smoking, dyslipidemia, hypertension, and obesity. Hereditary corneal dystrophies served as a negative control for the outcomes of interest, which comprised any RVO, central RVO (CRVO), branch RVO (BRVO), CRAO, and branch retinal artery blockage (BRAO).
Following propensity score matching based on the identified characteristics, the HbSS cohort consisted of 10,802 patients, the HbSC cohort of 4296 patients, and the sickle cell trait group of 15,249 individuals. As a result, there were 10,802 in the cohort matched for HbSS, 4206 in the cohort matched for HbSC, and 15,249 in the cohort matched for sickle cell trait.
Analysis revealed that the individuals with HbSS had a 2.33 times increased chance of developing any kind of RVO when compared to matched controls without SCD. The individuals with HbSS had a 4.90 times greater chance of developing BRAO and a 2.71 times higher risk of developing CRAO than the people without SCD.
The individuals with HbSC disease had a 3.14 times greater chance of getting any RVO when compared against their matched controls without SCD. However, the study found that patients with sickle cell trait had no statistically increased risk of having any kind of RVO. Overall, patients with HbSS sickle cell illness have a higher chance of developing retinal vascular occlusions, notably CRAO and BRAO, than the patients without sickle cell disease.
Source:
Kaufmann, G. T., Russell, M., Shukla, P., Singh, R. P., & Talcott, K. E. (2024). Retrospective Cohort Study of Sickle Cell Disease and Large Vessel Retinal Vascular Occlusion Risk in a National US Database. In Ophthalmology Retina. Elsevier BV. https://doi.org/10.1016/j.oret.2024.07.013

Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our Terms of Use, Privacy Policy, and Advertisement Policy.
For further details, please review our Full Disclaimer.

0 Comments

Post a comment

Please login to post a comment.

No comments yet. Be the first to comment!